Name: Awkward timing on opioids
Brand: thedesertreview.com
SKU: thedesertreview-com-1
Availability: OnlineOnly

critic

Awkward timing on opioids

preview


                                
                                
                                
                                From CalMatters health reporter&nbsp;Ana B. Ibarra:California Attorney General Rob Bonta on Friday&nbsp;announced a $273 million multistate settlement&nbsp;with New Jersey-based Amneal Pharmaceuticals for the drug manufacturer’s alleged failure to report suspicious opioid orders, and as a consequence&nbsp;contributing to the opioid epidemic.&nbsp;If the name “Amneal Pharmaceuticals” rings a bell, it’s because just days earlier Gov. Newsom and state health officials announced a deal with the same company to&nbsp;procure naloxone, the overdose reversal medication, at a cheaper price than currently available. That agreement locks that state in as a long-term customer to the company.Under the opioid settlement agreement that is yet to be finalized, Amneal will pay states a total of $92.5 million in cash and $180 million in naloxone products over a 10-year period. In a statement, Amneal said the settlement would resolve all pending lawsuits filed by states against the company.The company did not admit any wrongdoing.&nbsp;To date, California has secured $4.25 billion in opioid settlement funds that it uses on programs such as distributing naloxone and training substance use providers. Since 2018, the state has been purchasing the overdose reversal medication and distributing it to schools, law enforcement, county health departments and community harm reduction programs.&nbsp;Starting this month, California will be able to buy more naloxone because of the lower price it secured from Amneal: $24 for a two-unit nasal spray pack instead of the current price of $41.The Department of Health Care Access and Information, which is overseeing the naloxone contract, said it learned that Amneal was named in opioid litigation as it vetted proposals, but prioritized price, production capacity and other factorsRead more&nbsp;in the story.
                                
                                



                                
                                
                                
                                From CalMatters health reporter&nbsp;Ana B. Ibarra:California Attorney General Rob Bonta on Friday&nbsp;announced a $273 million multistate settlement&nbsp;with New Jersey-based Amneal Pharmaceuticals for the drug manufacturer’s alleged failure to report suspicious opioid orders, and as a consequence&nbsp;contributing to the opioid epidemic.&nbsp;If the name “Amneal Pharmaceuticals” rings a bell, it’s because just days earlier Gov. Newsom and state health...

public

CalMatters

thedesertreview.com

Credible

Speculation

Anecdotal Evidence

Generalization

Stacking the Deck

Appeal to Authority

Straw Man

Slippery Slope

Emotional Appeal

Red Herring

False Dilemma

Illogical

Moral Equivalency

Ad Hominem

Correlation w/o Causation

Semantics

Begging the Question

Faulty Analogy

Non Sequitur

Bandwagon

Dogmatism

Failing Occam's Razor

Biased

Pure Opinion

Hit Piece

Racial Bias

National Bias

Religious Bias

Financial Incentive

Political Agenda

Gender Bias

Misused Image/Video

Study Misinterpreted

Mistake

Misused Term

Science Misrepresented

Factual Error

Satire

Surface Level

Lack of Reliable Sources

Sensational

Not Credible

Investigative

Balanced

Well Sourced

Great Context

sports

entertainment

U.S.

international

business

technology

science

culture

politics

media

health

Awkward timing on opioids

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS